» Articles » PMID: 20530700

The Difficulty of Targeting Cancer Stem Cell Niches

Overview
Journal Clin Cancer Res
Specialty Oncology
Date 2010 Jun 10
PMID 20530700
Citations 66
Authors
Affiliations
Soon will be listed here.
Abstract

Normal stem cell niches typically are identified by their distinctive anatomical features and by association with tissue-specific stem cells. Identifying cancer stem cell (CSC) niches presents a special problem because there are few if any common anatomical features among tumors, and the physical phenotypes that reportedly describe the CSCs as entities may be subject to the host's microenvironment, sex, and tumor stage. Irrespective of a niche's location, the occupant's phenotype, or the precise molecular composition, all niches must do basically the same thing: maintain the activities in a stem cell that define it as such. Therefore, a potentially successful strategy, both for elaborating a molecular and cellular portrait of a CSC niche, and for therapeutically targeting them, is to identify components in the tumor microenvironment that are required for maintaining the functions of self-renewal, differentiation, and quiescence in the face of cytotoxic therapeutic regimens.

Citing Articles

Exploring the dynamic interplay between cancer stem cells and the tumor microenvironment: implications for novel therapeutic strategies.

Li Y, Fang Y, Lyu Z, Zhu Y, Yang L J Transl Med. 2023; 21(1):686.

PMID: 37784157 PMC: 10546755. DOI: 10.1186/s12967-023-04575-9.


Daunorubicin can eliminate iPS-derived cancer stem cells via ICAD/CAD-independent DNA fragmentation.

Seno A, Mizutani A, Aizawa K, Onoue R, Masuda J, Ochi N Cancer Drug Resist. 2022; 2(2):335-350.

PMID: 35582720 PMC: 8992628. DOI: 10.20517/cdr.2019.01.


Genetic Clonality as the Hallmark Driving Evolution of Non-Small Cell Lung Cancer.

Nicos M, Krawczyk P Cancers (Basel). 2022; 14(7).

PMID: 35406585 PMC: 8998004. DOI: 10.3390/cancers14071813.


Nanoparticle-Based RNAi Therapeutics Targeting Cancer Stem Cells: Update and Prospective.

Tang Y, Chen Y, Zhang Z, Tang B, Zhou Z, Chen H Pharmaceutics. 2021; 13(12).

PMID: 34959397 PMC: 8708448. DOI: 10.3390/pharmaceutics13122116.


M2 macrophage microvesicle-inspired nanovehicles improve accessibility to cancer cells and cancer stem cells in tumors.

Wang Y, Gong X, Li J, Wang H, Xu X, Wu Y J Nanobiotechnology. 2021; 19(1):397.

PMID: 34838042 PMC: 8627085. DOI: 10.1186/s12951-021-01143-5.


References
1.
Pannuti A, Foreman K, Rizzo P, Osipo C, Golde T, Osborne B . Targeting Notch to target cancer stem cells. Clin Cancer Res. 2010; 16(12):3141-52. PMC: 3008160. DOI: 10.1158/1078-0432.CCR-09-2823. View

2.
Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Minden M . A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994; 367(6464):645-8. DOI: 10.1038/367645a0. View

3.
Yoshida T . Contributions of the ascites hepatoma to the concept of malignancy of cancer. Ann N Y Acad Sci. 1956; 63(5):852-81. DOI: 10.1111/j.1749-6632.1956.tb50897.x. View

4.
OBrien C, Pollett A, Gallinger S, Dick J . A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 2006; 445(7123):106-10. DOI: 10.1038/nature05372. View

5.
Asselin-Labat M, Sutherland K, Barker H, Thomas R, Shackleton M, Forrest N . Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation. Nat Cell Biol. 2006; 9(2):201-9. DOI: 10.1038/ncb1530. View